Bone marrow transplantation for CD40 ligand deficiency: a single centre experience

Area of Science:

• Immunology
• Hematology
• Pediatric Medicine

Background:

• CD40 ligand (CD40L) deficiency is a rare X-linked immunodeficiency causing recurrent bacterial infections, enteritis, and liver cirrhosis.
• Bone marrow transplantation (BMT) is the only known cure for CD40L deficiency.
• Patients often present with severe infections and organ damage prior to BMT.

Purpose of the Study:

• To retrospectively analyze the outcomes of bone marrow transplantation for CD40L deficiency at a single center.
• To identify factors influencing survival and immune reconstitution post-BMT.

Main Methods:

• Retrospective case note analysis of eight boys with CD40L deficiency who underwent BMT between 1988 and 2000.
• Analysis of pre-transplant data, transplant details (donor type, HLA match), conditioning, and post-transplant outcomes (infections, engraftment, immune function).

Main Results:

• Four out of eight patients survived with normal immune function following BMT.
• Survival was associated with younger age at transplantation and normal liver histology.
• Six patients had prior Pneumocystis carinii pneumonia, and three had liver damage before transplant.

Conclusions:

• Bone marrow transplantation can be a curative treatment for CD40L deficiency.
• Optimal outcomes are linked to younger patient age and preserved liver histology at the time of transplantation.
• Further research into optimizing BMT strategies for CD40L deficiency is warranted.